Myriad Genetics Partners with Pathomiq to Add AI Technology Platform to its Oncology Portfolio
February 25, 2025
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests